The tweet was deleted by the author.
But we saved everything 🙂.
Gilead Sciences has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases.
This strategic move aims to bolster Gilead Sciences presence in the rapidly evolving autoimmune disease treatment landscape. Ouro Medicines brings a pipeline of innovative therapies targeting immune system disorders, underscoring Gilead Sciences commitment to diversifying its biopharmaceutical portfolio. Financial terms of the transaction were not disclosed.
View post on X Loading...
Gilead Sciences has recently advanced HIV prevention initiatives by leveraging music and community engagement at SXSW, as detailed in recent coverage. The company also began a crossover clinical trial targeting metastatic triple negative breast cancer, according to a separate report. These efforts reflect a continued focus on expanding Gilead’s research and development across multiple disease areas.